
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a promising biopharmaceutical company with an innovative approach to genetic medicine. Their focus on editing RNA instead of DNA enables them to target a wider range of diseases and provide a more precise and tunable treatment. The company has shown promising results in their preclinical studies, with their lead drug candidate, KRRO-121, demonstrating effective ammonia reduction and minimal side effects in both mouse and non-human primate models. With a robust portfolio of programs and a solid financial position, Korro Bio has the potential for significant growth and success in the biopharmaceutical industry.
Bears say
Korro Bio is a relatively new company and has a small portfolio of differentiated programs in the early stages of development. Despite promising preclinical data and potential market exclusivity from orphan drug designations, the company faces significant competition in the biopharmaceutical industry. Additionally, the failure of its KRRO-110 AATD program and potential delays in advancing pipeline candidates in clinical trials could lead to downward pressure on the stock. There is also the risk of discrepancies between the Company’s interpretations of data and those of regulatory authorities, possibly limiting the potential indications for its therapeutic products.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares